Please login to the form below

Not currently logged in

Aesica to buy UCB's German/ Italian sites

Leading UK pharmaceutical manufacturer, Aesica, has agreed to acquire UCB's manufacturing businesses in Germany and Italy

UCB and Aesica have agreed that Aesica will acquire current UCB manufacturing businesses in Germany and Italy.

The agreement includes the manufacturing sites in the German cities of Monheim and Zwickau, as well as Pianezza in Italy, and is part of UCB's strategy to optimise its manufacturing network in line with the evolution of its portfolio. The move will also secure the long-term supply of UCB's products and a future for the sites and their employees, according to UCB CEO Roch Doliveux.

Doliveux stated: "UCB's product portfolio has been changing significantly, which reduced UCB's need for large manufacturing capacity for chemical entities, while increasing its biotech requirements."

Approximately 600 employees in the three affected sites will be transferred to Aesica.

CEO of Aesica, Dr Robert Hardy, said: "The acquisition of the three manufacturing sites from UCB is strategically crucial for Aesica as we extend and enhance our current offering and presence in Europe. We hope to fully utilise the expertise and knowledge across the current team at UCB to achieve our vision of becoming the leading supplier of formulated products and active pharmaceutical ingredients to the global pharmaceutical and biotechnology industries.”

Subject to antitrust clearance, closing is expected for the first quarter of 2011. UCB's financial outlook for 2010 remains unchanged.

15th December 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch